CN111494224A - Whitening and spot-fading composition, skin care product and preparation method thereof - Google Patents
Whitening and spot-fading composition, skin care product and preparation method thereof Download PDFInfo
- Publication number
- CN111494224A CN111494224A CN202010549169.8A CN202010549169A CN111494224A CN 111494224 A CN111494224 A CN 111494224A CN 202010549169 A CN202010549169 A CN 202010549169A CN 111494224 A CN111494224 A CN 111494224A
- Authority
- CN
- China
- Prior art keywords
- parts
- whitening
- spot
- lightening
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 154
- 239000000203 mixture Substances 0.000 title claims abstract description 127
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000005562 fading Methods 0.000 title claims description 57
- 238000004519 manufacturing process Methods 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 54
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims description 93
- 239000000047 product Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- GKPMARPRXONRJX-BWJWTDLKSA-N (3s)-4-[[(2s,3s)-1-[[(2s)-1-amino-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical compound NC(=O)NCCC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN GKPMARPRXONRJX-BWJWTDLKSA-N 0.000 claims description 31
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical group OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 30
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 30
- 108010087806 Carnosine Proteins 0.000 claims description 30
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 30
- 229940044199 carnosine Drugs 0.000 claims description 30
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 30
- 229960005323 phenoxyethanol Drugs 0.000 claims description 30
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 29
- 244000042430 Rhodiola rosea Species 0.000 claims description 23
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 23
- 241001647091 Saxifraga granulata Species 0.000 claims description 22
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- 244000062241 Kaempferia galanga Species 0.000 claims description 18
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 18
- 241000219051 Fagopyrum Species 0.000 claims description 16
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 16
- 229940067866 dandelion extract Drugs 0.000 claims description 16
- 235000020691 dandelion extract Nutrition 0.000 claims description 16
- 229940064064 purslane extract Drugs 0.000 claims description 16
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 16
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 9
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 claims description 8
- 239000000679 carrageenan Substances 0.000 claims description 8
- 229920001525 carrageenan Polymers 0.000 claims description 8
- 229940113118 carrageenan Drugs 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 235000018553 tannin Nutrition 0.000 claims description 8
- 229920001864 tannin Polymers 0.000 claims description 8
- 239000001648 tannin Substances 0.000 claims description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 7
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 7
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 235000013871 bee wax Nutrition 0.000 claims description 7
- 239000012166 beeswax Substances 0.000 claims description 7
- 235000010418 carrageenan Nutrition 0.000 claims description 7
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 7
- 229940086555 cyclomethicone Drugs 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 7
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- -1 polyglycerol-10 Chemical compound 0.000 claims description 3
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 229940043375 1,5-pentanediol Drugs 0.000 claims 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- 102000003425 Tyrosinase Human genes 0.000 abstract description 16
- 108060008724 Tyrosinase Proteins 0.000 abstract description 16
- 230000007760 free radical scavenging Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 20
- 239000002537 cosmetic Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000001815 facial effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 5
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010008570 Chloasma Diseases 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 3
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000245665 Taraxacum Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008101 melanin synthesis pathway Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a whitening and spot-lightening composition, a skin care product and a preparation method thereof, wherein the whitening and spot-lightening polypeptide composition and the whitening and spot-lightening herbal composition are specific, can effectively inhibit the generation of melanin and the activity of tyrosinase, have good free radical scavenging capacity, have obvious effect when being applied to the skin care product, have no side effect and have high safety.
Description
Technical Field
The invention relates to the field of skin care products, in particular to a whitening and spot-fading composition, a skin care product and a preparation method thereof.
Background
With the development of society, the material requirements of people are met, and gradually, people also pay great attention to the pursuit of mental and cultural construction and personal images, which promotes the vigorous development of the cosmetic industry.
Along with the development of the cosmetic industry in China, new requirements are put on cosmetics under the market and national management requirements, and new domestic cosmetics with non-special purposes are put on record and formally implemented in 6-30 months in 2020. Particularly, it is noted that, in the "announcement on further clarifying the execution problems related to the registration of cosmetics" displayed on the official website of the national food and drug administration, it is also clearly stated that the whitening products will be classified as special-purpose cosmetics starting at 6 months of the next year, which means that nearly two whitening products in the market will be eliminated.
Hydroquinone, mercury and the like are used as common functional components of whitening spot-lightening cosmetics due to quick effect of whitening efficacy and low cost in the modern beauty community, but skin cancer is caused by repeated and serious spots caused by long-term use, and the hydroquinone, the mercury and the like are forbidden substances in the cosmetics specified in the cosmetic hygiene code (2007 edition). Therefore, it has been desired by beauty-conscious people to obtain a safe and effective whitening and spot-lightening ingredient.
The whitening and spot-lightening products on the current market mainly comprise three types of functional components: 1. the whitening agent for inhibiting melanin generation mainly comprises arbutin and its derivatives, kojic acid and its derivatives, vitamin C and its derivatives, etc., and can inhibit melanin generation by inhibiting tyrosinase activity; 2. the whitening agent for blocking melanin transfer mainly comprises azelaic acid, nicotinamide and the like, and can reduce the transfer speed of melanosomes to keratinocytes and reduce the melanin content of each epidermal cell layer; 3. the exfoliating agent mainly comprises fruit acid, keratolytic enzyme and the like, and the substances accelerate the exfoliation of the stratum corneum and promote the metabolism of the epidermis by softening the stratum corneum so that melanosomes entering the epidermis are exfoliated along with the rapid renewal of the epidermis; the above whitening agents have problems that the effect is not remarkable although they are highly safe, the effect is easily repeated once the agent is not used, the agent is easily oxidized and denatured due to its nature, and a large amount of active ingredients is required if the agent is required to take effect quickly, but the skin is easily intolerant to the large amount.
Although natural botanical drugs are favored for their natural, harmless, and non-side effects, they also have problems of low absorption rate and slow onset of action.
With the development of polypeptide industry, the application of polypeptide is gradually developed from biological research and medical research to the application of daily used articles, such as cosmetic addition: for example, the current cosmetic polypeptides such as GHK (tripeptide-1) with intense fire have various action modes, and how to effectively match different cosmetic peptides to promote the efficacy of the cosmetic peptides is a hot spot of research in the field.
Disclosure of Invention
The invention mainly solves the technical problem of providing a whitening and spot-lightening composition and a skin care product, which can effectively inhibit melanin generation, whiten skin and remove spots.
In order to solve the technical problems, the invention adopts a technical scheme that:
the whitening and spot-fading composition comprises a whitening and spot-fading polypeptide composition, wherein the whitening and spot-fading polypeptide composition comprises the following components in parts by weight: nonapeptide-10.05-0.5 part, hexapeptide-20.001-0.5 part, component a;
the component a is one or more selected from 5-20 parts of carnosine-10.05-0.5 part of tripeptide-10, 0.01-0.5 part of tripeptide-10 citrulline and 0. 80.05-0.5 part of acetyl hexapeptide.
Further, the whitening and spot-lightening polypeptide composition comprises the following components in parts by weight: nonapeptide-10.05-0.2 parts, hexapeptide-20.05-0.02 parts, component a;
the component a is one or more selected from 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide, 0.05-0.2 parts of tripeptide-10 citrulline and 80.1-0.2 parts of acetyl hexapeptide;
further, the component a is selected from one of the following (1) to (6):
(1) 5-15 parts of carnosine;
(2) 10.05-0.2 parts of tripeptide-10 and 0.05-0.2 parts of tripeptide-10 citrulline;
(3) 80.1-0.2 parts of acetyl hexapeptide;
(4) 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide-10 and 0.05-0.2 parts of tripeptide-10 citrulline;
(5) 5-15 parts of carnosine and 80.1-0.2 parts of acetyl hexapeptide;
(6) 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide-10, 0.05-0.2 parts of tripeptide-10 citrulline and 80.1-0.2 parts of acetyl hexapeptide;
furthermore, the whitening and spot-lightening composition comprises the following components in parts by weight: nonapeptide-10.1 parts, hexapeptide-20.1 parts, carnosine 10 parts, tripeptide-10 citrulline 0.1 part, tripeptide-10.2 parts, acetyl hexapeptide-80.2 parts
Further, the whitening and spot-lightening herbal composition also comprises a whitening and spot-lightening herbal composition, and the whitening and spot-lightening herbal composition comprises the following components in parts by weight: 2-6 parts of dandelion extract, 2-6 parts of galangal extract and a component b;
the component b is selected from one or more of 2-6 parts of rhodiola rosea extract, 2-6 parts of saxifrage extract, 0.05-0.15 part of purslane extract and 0.05-0.15 part of buckwheat extract;
further, the component b is selected from one of the following (7) to (10):
(7) 2-6 parts of rhodiola rosea extract;
(8) 2-6 parts of saxifrage extract;
(9) 2-6 parts of rhodiola rosea extract and 2-6 parts of saxifrage extract;
(10) 2-6 parts of rhodiola rosea extract, 2-6 parts of saxifrage extract, 0.05-0.15 part of purslane extract and 0.05-0.15 part of buckwheat extract;
furthermore, the whitening and spot-lightening herbal composition comprises the following components in parts by weight: 4 parts of rhodiola rosea extract, 4 parts of saxifrage extract, 4 parts of dandelion extract, 4 parts of galangal extract, 0.1 part of purslane extract and 0.1 part of buckwheat extract.
Further, the whitening and spot-lightening polypeptide composition or the whitening and spot-lightening herbal composition further comprises one or more of a solvent, an auxiliary preservative and a preservative.
Further, the solvent or the auxiliary preservative is selected from butanediol and/or pentanediol, and the preservative is phenoxyethanol;
furthermore, the whitening and spot-lightening polypeptide composition or the whitening and spot-lightening herbal composition further comprises 10-30 parts of butanediol, 2-8 parts of pentanediol and 0.2-1.5 parts of phenoxyethanol, preferably 20 parts of butanediol, 5 parts of pentanediol and 1 part of phenoxyethanol.
In a specific embodiment of the invention, the whitening and spot-lightening polypeptide composition comprises the following components in parts by weight: nonapeptide-10.1 parts, hexapeptide-20.1 parts, carnosine 10 parts, tripeptide-10.2 parts, tripeptide-10 citrulline 0.1 part, acetyl hexapeptide-80.2 parts, butanediol 20 parts, pentanediol 5 parts, phenoxyethanol 1 part and water 63.35 parts.
In one embodiment of the invention, the whitening and spot-lightening herbal composition comprises the following components in parts by weight: 4 parts of rhodiola rosea extract, 4 parts of dandelion extract, 4 parts of galangal extract, 4 parts of saxifrage extract, 0.1 part of purslane extract, 0.1 part of buckwheat extract, 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol and 57.8 parts of water.
The invention also provides a preparation method of the whitening and spot-lightening composition, which comprises the following steps: mixing the raw materials; if the raw materials contain Chinese medicinal extract, removing tannin from the Chinese medicinal extract, and mixing with the rest components;
further, the whitening and spot-lightening polypeptide composition or the whitening and spot-lightening herbal composition is prepared respectively and then mixed.
The invention also provides a product for whitening and lightening spots, which comprises any whitening and lightening spot composition;
further, the content of the whitening and spot-lightening composition is 0.5-5%, preferably 1-3%;
the product is a skin care product or a skin external medicine.
Further, the product for whitening and lightening the spots comprises the following components in parts by weight: 0.5-5 parts of any whitening and spot-fading composition, 1-5 parts of isononyl isononanoate, 1-5 parts of cyclomethicone, 1-5 parts of dimethicone, 01-3 parts of cetostearyl alcohol, 1-2 parts of fatty monoglyceride, 0.5-2 parts of beeswax, 0.5-2 parts of stearic acid, 3-7 parts of glycerol, 5-15 parts of butanediol, 101-3 parts of polyglycerol-101, 0.1-0.3 part of carrageenan, 55-70 parts of water, 0.2-0.8 part of phenoxyethanol and 0.02-0.08 part of chlorophenyl glycoside ether;
further comprises the following steps: 1 part of any whitening spot-lightening polypeptide composition, 1 part of any whitening spot-lightening herbal composition, 3 parts of isononyl isononanoate, 3 parts of cyclomethicone, 2 parts of dimethicone, 1.5 parts of cetostearyl alcohol, 1.5 parts of fatty monoglyceride, 1 part of beeswax, 1 part of stearic acid, 5 parts of glycerol, 7 parts of butanediol, 102 parts of polyglycerol-carrageenan, 0.2 part of carrageenan, 66.25 parts of water, 0.5 part of phenoxyethanol and 0.05 part of chlorophenyl glycoside ether.
The invention also provides a preparation method of the whitening and spot-lightening product, which comprises the following steps:
(1) preparation of aqueous phase: mixing glycerol, butanediol, polyglycerol-10, carrageenan, water and chlorphenesin, heating to 80-90 ℃, and preserving heat for 10-60 min;
(2) preparation of oil phase: mixing isononyl isononanoate, cyclomethicone, dimethicone, cetostearyl alcohol, fatty acid monoglyceride, beeswax and stearic acid, heating to 70-80 deg.C, and keeping the temperature for 5-30 min;
(3) emulsification: mixing the water phase and the oil phase, homogenizing, and cooling to below 45 deg.C to obtain semi-finished product;
(4) and adjusting the pH value of the semi-finished product to 5.5-6.5, and then mixing the whitening and spot-fading polypeptide composition and/or the whitening and spot-fading herbal composition with the semi-finished product and phenoxyethanol.
The invention has the beneficial effects that:
(1) according to the whitening and spot-fading polypeptide composition, the specific polypeptides are combined, so that the generation of melanin can be effectively inhibited, experiments prove that the combination of the components has an obvious synergistic effect, the inhibition effect after combination is superior to that of the inhibition effect of the individual effect, the production of melanin can be prevented, the melanin synthesis pathway can be blocked, and the whitening and spot-fading polypeptide composition is a bionic peptide with high safety coefficient, and has high efficiency and high skin-friendly property.
(2) The whitening and spot-lightening herbal composition can effectively inhibit tyrosinase activity and has good free radical scavenging capacity by combining specific plant extracts, tests prove that the combination of all the components has obvious synergistic effect, the combined inhibiting effect is better than the inhibiting effect of the single action, the existing pigmentation spots can be lightened from inhibiting the tyrosinase activity to resisting oxidation of melanin deposited on the surface layer, and the skin and the muscle bottom can be adjusted and strengthened.
(3) According to the whitening and spot-fading composition, after the whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition are combined, the whitening and spot-fading effects are further improved, the effect is superior to that of the whitening and spot-fading polypeptide composition or the whitening and spot-fading herbal composition which is singly used, and the combination of the whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition has a certain synergistic effect.
(4) The whitening and spot-fading product is added with the whitening and spot-fading composition, after the whitening and spot-fading product is used by volunteers, the skin color is obviously improved, 40-50% of spots can be faded, the effect is obvious, no toxicity or side effect is caused, the property is stable, and the whitening and spot-fading product has a wide market prospect.
Detailed Description
The technical solutions of the present invention are described clearly and completely below, and it is obvious that the described embodiments are some, not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the specific embodiment of the invention, the rhodiola rosea extract, the galangal extract, the dandelion extract and the saxifrage extract are the existing commercial products (the product specification: water extract, the extraction ratio is 10: 1, namely 10 parts of dry weight traditional Chinese medicine extract is 1 part of dry weight traditional Chinese medicine extract);
the herba Portulacae extractive solution and semen Fagopyri Esculenti extractive solution are commercially available products, wherein the mass concentration of the extract (dry weight) is 1%.
Example 1
(1) Preparing a whitening and spot-lightening polypeptide composition:
uniformly mixing 20 parts of butanediol, 5 parts of pentanediol, 10 parts of carnosine, 10.1 parts of nonapeptide, 0.1 part of tripeptide-10 citrulline, 20.1 parts of hexapeptide, 10.2 parts of tripeptide, 80.2 parts of acetyl hexapeptide, 1 part of phenoxyethanol and 63.35 parts of pure water to obtain the whitening and spot-lightening polypeptide composition.
(2) Preparing a whitening and spot-fading herbal composition:
mixing 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol, 4 parts of rhodiola rosea extract, 4 parts of dandelion extract, 4 parts of galangal extract, 4 parts of saxifrage extract and 38 parts of pure water, stirring for dissolving, removing tannin by an acid-base method, adjusting the pH to 4.5-5.5, adding 10 parts of purslane extract and 10 parts of buckwheat extract, and obtaining the whitening and spot-lightening herbal composition.
(3) Preparing the whitening and spot-lightening composition
And mixing the prepared whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition according to the mass ratio of 1:1 to obtain the whitening and spot-fading composition.
Example 2
(1) Preparing a whitening and spot-lightening polypeptide composition:
uniformly mixing 20 parts of butanediol, 5 parts of pentanediol, 10 parts of carnosine, 10.1 parts of nonapeptide, 0.1 part of tripeptide-10 citrulline, 20.1 parts of hexapeptide, 10.1 parts of tripeptide, 80.1 parts of acetyl hexapeptide, 1 part of phenoxyethanol and 63.5 parts of pure water to obtain the whitening and spot-fading polypeptide composition.
(2) Preparing a whitening and spot-fading herbal composition:
mixing 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol, 2 parts of rhodiola rosea extract, 2 parts of dandelion extract, 2 parts of galangal extract, 2 parts of saxifrage extract and 38 parts of pure water, stirring for dissolving, removing tannin by an acid-base method, adjusting the pH to 4.5-5.5, adding 15 parts of purslane extract and 15 parts of buckwheat extract, and obtaining the whitening and spot-lightening herbal composition.
(3) Preparing the whitening and spot-lightening composition
And mixing the prepared whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition according to the mass ratio of 1:1 to obtain the whitening and spot-fading composition.
Example 3
(1) Preparing a whitening and spot-lightening polypeptide composition:
uniformly mixing 20 parts of butanediol, 5 parts of pentanediol, 5 parts of carnosine, 10.05 parts of nonapeptide, 0.2 part of tripeptide-10 citrulline, 20.2 parts of hexapeptide, 10.1 parts of tripeptide, 80.1 parts of acetyl hexapeptide, 1 part of phenoxyethanol and 68.35 parts of pure water to obtain the whitening and spot-fading polypeptide composition.
(2) Preparing a whitening and spot-fading herbal composition:
mixing 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol, 6 parts of rhodiola rosea extract, 6 parts of dandelion extract, 6 parts of galangal extract, 6 parts of saxifrage extract and 30 parts of pure water, stirring for dissolving, removing tannin by an acid-base method, adjusting the pH to 4.5-5.5, adding 10 parts of purslane extract and 10 parts of buckwheat extract, and obtaining the whitening and spot-lightening herbal composition.
(3) Preparing the whitening and spot-lightening composition
And mixing the prepared whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition according to the mass ratio of 1:1 to obtain the whitening and spot-fading composition.
Example 4
(1) Preparing a whitening and spot-lightening polypeptide composition:
uniformly mixing 20 parts of butanediol, 5 parts of pentanediol, 20 parts of carnosine, 10.2 parts of nonapeptide, 0.05 part of tripeptide-10 citrulline, 20.05 parts of hexapeptide, 10.1 parts of tripeptide, 80.1 parts of acetyl hexapeptide, 1 part of phenoxyethanol and 53.5 parts of pure water to obtain the whitening and spot-lightening polypeptide composition.
(2) Preparing a whitening and spot-fading herbal composition:
mixing 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol, 4 parts of rhodiola rosea extract, 4 parts of dandelion extract, 4 parts of galangal extract, 4 parts of saxifrage extract and 48 parts of pure water, stirring for dissolving, removing tannin by an acid-base method, adjusting the pH to 4.5-5.5, adding 5 parts of purslane extract and 5 parts of buckwheat extract, and obtaining the whitening and spot-lightening herbal composition.
(3) Preparing the whitening and spot-lightening composition
And mixing the prepared whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition according to the mass ratio of 1:1 to obtain the whitening and spot-fading composition.
Example 5
(1) Preparing a whitening and spot-lightening polypeptide composition:
uniformly mixing 20 parts of butanediol, 5 parts of pentanediol, 5 parts of carnosine, 10.1 parts of nonapeptide, 0.1 part of tripeptide-10 citrulline, 20.1 parts of hexapeptide, 10.2 parts of tripeptide, 80.2 parts of acetyl hexapeptide, 1 part of phenoxyethanol and 63.35 parts of pure water to obtain the whitening and spot-fading polypeptide composition.
(2) Preparing a whitening and spot-fading herbal composition:
mixing 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol, 5 parts of rhodiola rosea extract, 5 parts of dandelion extract, 5 parts of galangal extract, 5 parts of saxifrage extract and 48 parts of pure water, stirring for dissolving, removing tannin by an acid-base method, adjusting the pH to 4.5-5.5, adding 5 parts of purslane extract and 5 parts of buckwheat extract, and obtaining the whitening and spot-lightening herbal composition.
(3) Preparing the whitening and spot-lightening composition
And mixing the prepared whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition according to the mass ratio of 1:1 to obtain the whitening and spot-fading composition.
The whitening and spot-fading effects of the whitening and spot-fading polypeptide composition and the whitening and spot-fading herbal composition of the invention and the synergistic effect of the components are verified through the following test examples 1-2:
in the skin care product, effective components cannot completely enter a cell layer to act on cells due to the obstruction of a skin surface layer, and polypeptide components in a cell experiment are directly contacted with the cells, so the polypeptide concentration in the cell experiment is much lower than that in a product formula.
Test example 1
1. Experimental materials and instruments
Materials: the cell strain is mouse melanoma cell B16; DMEM-high sugar medium, dimethyl sulfoxide (DMSO), trypsin, RIPA lysate and tetramethyl azozolium (TMM); the detection sample is the peptides produced by me.
The instrument comprises the following steps: an electronic analytical balance, a high-speed refrigerated centrifuge, an ultra-clean workbench, a carbon dioxide incubator, an inverted microscope, a liquid nitrogen biological container and an enzyme-labeling instrument.
2. The experimental method comprises the following steps:
MTT detection of cell proliferation rate mouse melanoma cell B16 in 4 × 104Inoculating each cell/well in 96-well plate, after cell adherence, replacing culture solution (DMEM-high sugar culture medium) with fresh culture solution containing different peptide combinations for 1 time, setting up 3 repeated experimental groups in each group, at 37 deg.C and 5% CO2After 24h of culture in the incubator, the culture solution is aspirated off, 100. mu.l of MTT solution (5mg/ml) is added to each well, the supernatant is aspirated off after 4h of subsequent culture, 150. mu.l of DMSO is added to each well, shaking is carried out for 15min, the precipitate is fully dissolved, and the absorbance is measured by a microplate reader at 570 nm.
Measuring melanin content by measuring cell concentration of 1 × 105The cell suspension of B16/ml was inoculated in 6-well plates at 2ml per well, and the plates were incubated at 37 ℃ with 5% CO2After culturing cells in an incubator for 24 hours, removing the culture solution by suction, replacing the culture solution with a fresh culture solution containing different peptide combinations for 1 time, repeating each group with three holes, after 72 hours, removing the supernatant, washing with 0.01M PBS buffer solution with pH7.4 for 1 time, digesting the cells in the pore plate with pancreatin solution with the concentration of 0.25% (W/V), collecting the cells in an EP tube after digestion is stopped, centrifuging for 3 minutes, removing the supernatant, adding 100 mu l of RIPA lysate into each hole, fully reflecting the reaction, centrifuging, removing the supernatant, adding 150 mu L1 mol/L NaOH, placing the cell in a thermostat at 95 ℃ for 1 hour to dissolve melanin, measuring absorbance at 450nm by an enzyme labeling instrument, and calculating the melanin content of each administration hole.
Melanin content-melanin content OD 450/cell proliferation rate OD570 × 100%.
The following test groups were set up:
control group: a blank PBS group;
group 1: contains carnosine 10 mu g/ml;
group 2: contains nonapeptide-10.1 μ g/ml and hexapeptide-20.1 μ g/ml, and is classified into one group because the melanin inhibiting effect is proved by authority;
group 3: comprises tripeptide-10.01 mug/ml and tripeptide-10 citrulline 0.1 mug/ml;
group 4: contains acetyl hexapeptide-80.2 mug/ml;
group 5: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml;
group 6: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, tripeptide-10.1 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml;
group 7: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, acetyl hexapeptide-80.2 μ g/ml;
group 8: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, tripeptide-10.1 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml;
group 9: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, acetyl hexapeptide-80.2 μ g/ml;
group 10: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, tripeptide-10.1 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml, acetyl hexapeptide-80.2 μ g/ml;
group 11: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, tripeptide-10.1 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml, acetyl hexapeptide-80.2 μ g/ml;
group 12: contains nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, tripeptide-10.1 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml, acetyl hexapeptide-80.1 μ g/ml;
group 13: the content of nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, tripeptide-10.05 μ g/ml, tripeptide-10 citrulline 0.05 μ g/ml, acetyl hexapeptide-80.2 μ g/ml.
Group 14: the content of nonapeptide-10.1 μ g/ml, hexapeptide-20.1 μ g/ml, carnosine 10 μ g/ml, tripeptide-10.2 μ g/ml, tripeptide-10 citrulline 0.1 μ g/ml, acetyl hexapeptide-80.2 μ g/ml.
The results of the experiment are shown in table 1:
TABLE 1
The results show that: nonapeptide-1 in combination with hexapeptide-2 (group 2) inhibited melanin production; carnosine (group 1) had some effect but was less pronounced than nonapeptide-1 & hexapeptide-2 (group 2); the combination of tripeptide-1 with the tripeptide-10 citrulline (group 3) and acetyl hexapeptide-8 (group 4) had little inhibitory effect. However, after three or more polypeptides are compounded, the inhibition effect is obviously enhanced: combination of nonapeptide-1, hexapeptide-2 and carnosine (group 5), combination of nonapeptide-1, hexapeptide-2, tripeptide-1 and tripeptide-10 citrulline (group 6), and combination of tripeptide-1, tripeptide-10 citrulline and acetyl hexapeptide-8 (group 7), the effect of inhibiting melanin generation is significantly greater than that of group 2; the components are further added, the inhibiting effect of the groups 8-10 is enhanced compared with that of the groups 5-7, and the best effect is achieved when all six polypeptides, namely nonapeptide-1, hexapeptide-2, carnosine, tripeptide-1, tripeptide-10 citrulline and acetyl hexapeptide-8, are compounded (groups 11-14).
Test example 2
1. Experimental material and experimental instrument
95% ethanol, L-tyrosine, 1-diphenyl-2-trinitrophenyl hydrazine (DPPH), tyrosinase, disodium hydrogen phosphate, sodium dihydrogen phosphate;
a constant temperature water bath kettle and an ultraviolet spectrophotometer.
2. The preparation method of the natural herbal extract comprises the following steps:
mixing one or more of radix Rhodiolae extract, rhizoma Alpiniae Officinarum extract, herba Taraxaci extract, and herba Saxifragae extract (specific components and dosage are shown in data of each sample), adding butanediol 20g, pentanediol 5g, phenoxyethanol 1g, and pure water 56g, stirring for dissolving for 4 hr, and adding Ca (OH)2Adjusting the pH value of the plant solution to be more than 10.0, sequentially filtering with filter paper and a 0.45 micrometer filter membrane to remove tannin, adjusting the pH value of the obtained clear and transparent liquid with citric acid to be 4-6.5, standing for 24h, and sequentially filtering with filter paper and a 0.45 micrometer filter membrane to remove excessive Ca in the solution2+(ii) a And then adding the purslane extract and the buckwheat extract, and uniformly mixing to prepare a natural herbal extract.
The following sample groups were set, and the extract components contained in the sample groups were prepared according to the above preparation methods:
C1: 2g of rhodiola rosea extract;
C2: saxifraga stolonifera extract 2g；
C3: 1g of rhodiola rosea extract and 1g of saxifrage extract respectively;
C4: 1g of galangal extract and 1g of dandelion extract respectively;
C5: 5g of purslane extract and buckwheat extract respectively;
C6: 2g of rhodiola rosea extract, 1g of galangal and 1g of dandelion respectively;
C7: 2g of saxifrage extract, 1g of galangal and 1g of dandelion respectively;
C8: rhodiola rosea extract, saxifrage extract 1g respectively, galangal extract, dandelion extract 1g respectively;
C9: rhodiola rosea extract, saxifrage extract 1g respectively, galangal extract, dandelion extract 1g respectively, purslane extract and buckwheat extract 5g respectively.
The whitening effect is verified through tyrosinase activity inhibition experiments and DPPH free radical removal experiments.
Tyrosinase activity inhibition assay
Solution preparation:
tyrosine solution: 0.3 mol/ml; aqueous tyrosinase solution: 1.0 mg/ml; PBS buffer (phosphate buffer): 0.2M, pH 6.8;
l-tyrosinase solution and tyrosinase water solution, and storing at 4 deg.C in dark place.
The experimental method comprises the following steps:
according to the table 2, each group of samples was prepared by mixing the samples, PBS and L-tyrosine in a test tube, heating in a 37 ℃ water bath for 10min (to make the reaction temperature consistent and reduce the variation), adding tyrosinase, mixing uniformly, reacting at 37 ℃ for 10min, recording the absorbance in a 475nm ultraviolet spectrophotometer by using a quartz cuvette, and calculating the inhibition rate of tyrosinase [1- (Ac) (inhibition rate of tyrosinase is 1: [1- (Ac ]) according to the following formulax-Ac)/(At2-At1)]*100％
TABLE 2
(absorption: 475nm, three sets of parallel experiments, blank: PBS (2M, ph:6.8))
DPPH free radical scavenging experiment
Solution preparation:
DPPH solution (1, 1-diphenyl-2-trinitrophenylhydrazine): 0.05mg/ml (dissolved in 95% ethanol, sonicated for 5 min);
sample liquid: 5% sample solution + 95% pure ethanol;
the experimental method comprises the following steps:
each group of samples was added to a test tube according to table 3, mixed well and reacted for 30min in the dark, then detected in a 517nm uv spectrophotometer, and the recorded values were substituted into the following formula to calculate the radical scavenging rate.
Clearance rate ═ 1- (Ax-A)3)/A1]*100％。
TABLE 3
(absorption: 517nm, three groups in parallel, blank: 95% ethanol)
The measurement results are shown in Table 4:
TABLE 4
It is believed that the mechanism of melanin production is that tyrosine on melanin in melanocytes is catalyzed by tyrosinase, whereas ultraviolet light can cause tyrosinase activity and melanocyte activity to increase.
The results show that when the galangal extract, the dandelion extract and the rhodiola extract are compounded (C)6) Or mixing with herba Saxifragae extract (C)7) The components have synergistic effect, and the tyrosinase inhibition rate and the DPPH clearance rate are improved and are superior to those of C1、C2、C4Group (d); c8、C9The effect of the group is significantly better than that of group C3、C4、C5Group, description C3、C4、C5The herbal extracts of the group have synergistic effect, wherein C is9The herbal composition for whitening and lightening the spots has the optimal group effect, and the herbal composition for whitening and lightening the spots can inhibit the generation of pigment by inhibiting the activity of tyrosinase and further has the double effects of resisting oxidation of melanin deposited on the surface layer and lightening the spots.
The whitening and spot-lightening efficacy of the whitening and spot-lightening composition and the synergistic effect of the whitening and spot-lightening polypeptide composition and the whitening and spot-lightening herbal composition after being combined together are verified by the following test example 3:
test example 3
Preparing a whitening and spot-lightening skin care product:
1. preparation of aqueous phase: mixing, stirring and heating the water phase component and the chlorophenyl glycoside ether in the auxiliary material matrix to 85 ℃ at a stirring speed of 300-400 rpm, and preserving heat for 30 min;
2. preparation of oil phase: adding the oil phase components into a beaker, mixing, stirring and heating at a stirring speed of 300-400 rpm to 75 ℃, and keeping the temperature for 15 min;
3. emulsification: mixing the water phase and the oil phase which are uniformly dissolved, uniformly stirring the mixture by using a stirrer at the speed of 300-400 rpm, homogenizing the mixture for 5-10 min by using a homogenizer at the speed of 3000rpm, and naturally cooling the mixture to below 45 ℃ to prepare a semi-finished product for later use;
4. and (3) adjusting the pH value to 5.5-6.5 by using a pH regulator, adding the effective components into the semi-finished product, and mixing and stirring uniformly.
The skin care product with the following three formulas is prepared:
the oil phase and the water phase of the skin care product for whitening and lightening spots are the same, and the difference is only that the effective components are different:
the weight ratio of each substance is as follows:
oil phase: 3kg of isononyl isononanoate, 3kg of cyclomethicone, 2kg of polydimethylsiloxane, 1.5kg of cetostearyl alcohol, 1.5kg of fatty acid monoglyceride, 1kg of beeswax and 1kg of stearic acid;
water phase: 5kg of glycerin, 7kg of butanediol, 102 kg of polyglycerol, 0.2kg of carrageenan and 66.25kg of pure water;
preservative: 0.5kg of phenoxyethanol and 0.05kg of chlorophenyl glycoside ether;
whitening spot-lightening skin care product No. 1: 2kg of the whitening and spot-lightening composition prepared in example 1 as an effective component;
whitening spot-lightening skin care product No. 2: the effective components comprise 1kg of the whitening and spot-lightening polypeptide composition prepared in the example 1, and 0.4kg of butanediol, 0.02 part of phenoxyethanol and 1.48kg of pure water are added;
whitening spot-lightening skin care product No. 3: the effective components comprise 1kg of the whitening and spot-fading herbal composition prepared in the example 1, and 0.4kg of butanediol, 0.02 part of phenoxyethanol and 1.48kg of pure water are added.
The method comprises the steps of selecting 60 women with chloasma on the faces of 30-40 years old, randomly dividing the women into three groups, carrying out long-term experiments for 60 days by 20 people in each group, using the women once after washing the faces in the morning and evening, smearing the whole face, recording, detecting and analyzing facial stains of an experiencer before use, in use and after finishing by a magic mirror face imaging analysis system, and enabling the three groups of experiencers to have differences after 60 days:
skin care product No. 1 experimental group: fading the whole facial color spots by 40-50%;
skin care product No. 2 experimental group: fading the whole facial color spots by 25-30%;
skin care product No. 3 experimental group: and 5-10% of the whole facial color spot is faded.
Specific cases of some examples are listed below:
example 1:
when a certain sun is in age 32, the whitening spot-lightening cosmetic No. 3 is used, chloasma appears in the original facial condition, inflammation appears in the part with reduced skin quality, and the face color is yellow and dark; after the product No. 1 is continuously used for 60 days, facial color spots are not obviously lightened, the skin color is obviously lightened, and the skin inflammation is improved without adverse reaction.
Example 2:
when the whitening spot-fading cosmetic No. 2 is used for 33 years old and young girl, the original facial condition has chloasma, the cuticle is thin and red blood streaks appear, the skin is white but dark, after the product No. 2 is continuously used for 60 days, the facial speckles are faded by 25-30%, the red blood streaks are obviously improved, and the skin is brightened.
Example 3:
when the whitening spot-fading cosmetic 1 is used for a certain populus female in the age of 32 years, chloasma exists in the original facial condition, rough pores of the skin are enlarged, local inflammation occurs, the skin color is dark, pale, yellow and black under-eye circles, the facial spots are faded by 40-50% after the product 3 is used for 60 days, the original rough skin becomes tender, the skin inflammation is reduced, and the skin is bright, white and ruddy.
The whitening and spot-lightening polypeptide composition has a synergistic effect with a whitening and spot-lightening herbal composition, has remarkable freckle-removing and whitening effects on various stains and dark skin, has no toxic or side effect, and can obviously improve the skin quality.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. The whitening spot-lightening composition is characterized by comprising a whitening spot-lightening polypeptide composition, wherein the whitening spot-lightening polypeptide composition comprises the following components in parts by weight: nonapeptide-10.05-0.5 part, hexapeptide-20.001-0.5 part, component a;
the component a is one or more selected from 5-20 parts of carnosine-10.05-0.5 part of tripeptide-10, 0.01-0.5 part of tripeptide-10 citrulline and 0. 80.05-0.5 part of acetyl hexapeptide.
2. The whitening spot-lightening composition of claim 1, wherein the whitening spot-lightening polypeptide composition comprises the following components in parts by weight: nonapeptide-10.05-0.2 parts, hexapeptide-20.05-0.02 parts, component a;
the component a is one or more selected from 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide, 0.05-0.2 parts of tripeptide-10 citrulline and 80.1-0.2 parts of acetyl hexapeptide;
further, the component a is selected from one of the following (1) to (6):
(1) 5-15 parts of carnosine;
(2) 10.05-0.2 parts of tripeptide-10 and 0.05-0.2 parts of tripeptide-10 citrulline;
(3) 80.1-0.2 parts of acetyl hexapeptide;
(4) 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide-10 and 0.05-0.2 parts of tripeptide-10 citrulline;
(5) 5-15 parts of carnosine and 80.1-0.2 parts of acetyl hexapeptide;
(6) 5-15 parts of carnosine, 10.05-0.2 parts of tripeptide-10, 0.05-0.2 parts of tripeptide-10 citrulline and 80.1-0.2 parts of acetyl hexapeptide;
furthermore, the whitening and spot-lightening composition comprises the following components in parts by weight: nonapeptide-10.1 parts, hexapeptide-20.1 parts, carnosine 10 parts, tripeptide-10 citrulline 0.1 part, tripeptide-10.2 parts and acetyl hexapeptide-80.2 parts.
3. The whitening spot-lightening composition of claim 1, further comprising a whitening spot-lightening herbal composition, wherein the whitening spot-lightening herbal composition comprises the following components in parts by weight: 2-6 parts of dandelion extract, 2-6 parts of galangal extract and a component b;
the component b is selected from one or more of 2-6 parts of rhodiola rosea extract, 2-6 parts of saxifrage extract, 0.05-0.15 part of purslane extract and 0.05-0.15 part of buckwheat extract;
further, the component b is selected from one of the following (7) to (10):
(7) 2-6 parts of rhodiola rosea extract;
(8) 2-6 parts of saxifrage extract;
(9) 2-6 parts of rhodiola rosea extract and 2-6 parts of saxifrage extract;
(10) 2-6 parts of rhodiola rosea extract, 2-6 parts of saxifrage extract, 0.05-0.15 part of purslane extract and 0.05-0.15 part of buckwheat extract;
furthermore, the whitening and spot-lightening herbal composition comprises the following components in parts by weight: 4 parts of rhodiola rosea extract, 4 parts of saxifrage extract, 4 parts of dandelion extract, 4 parts of galangal extract, 0.1 part of purslane extract and 0.1 part of buckwheat extract.
4. The whitening spot-lightening composition according to any one of claims 1 to 3, wherein the whitening spot-lightening polypeptide composition or the whitening spot-lightening herbal composition further comprises one or more of a solvent, an auxiliary preservative and a preservative.
5. The whitening spot-lightening composition of claim 4, wherein the solvent or co-preservative is selected from butylene glycol and/or pentylene glycol, and the preservative is phenoxyethanol;
furthermore, the whitening spot-lightening polypeptide composition or the whitening spot-lightening herbal composition also comprises 10-30 parts of butanediol, 2-8 parts of pentanediol and 0.2-1.5 parts of phenoxyethanol, preferably 20 parts of butanediol, 5 parts of pentanediol and 1 part of phenoxyethanol.
6. The whitening spot-lightening composition of claim 4 or 5, wherein the whitening spot-lightening polypeptide composition comprises the following components in parts by weight: nonapeptide-10.1 parts, hexapeptide-20.1 parts, carnosine 10 parts, tripeptide-10.2 parts, tripeptide-10 citrulline 0.1 part, acetyl hexapeptide-80.2 parts, butanediol 20 parts, pentanediol 5 parts, phenoxyethanol 1 part and water 63.35 parts;
the whitening and spot-fading herbal composition comprises the following components in parts by weight: 4 parts of rhodiola rosea extract, 4 parts of dandelion extract, 4 parts of galangal extract, 4 parts of saxifrage extract, 0.1 part of purslane extract, 0.1 part of buckwheat extract, 20 parts of butanediol, 5 parts of pentanediol, 1 part of phenoxyethanol and 57.8 parts of water.
7. The preparation method of the whitening and spot-lightening composition according to any one of claims 1 to 6, which comprises the following steps: mixing the raw materials; if the raw materials contain Chinese medicinal extract, removing tannin from the Chinese medicinal extract, and mixing with the rest components;
further, the whitening and spot-lightening polypeptide composition or the whitening and spot-lightening herbal composition is prepared respectively and then mixed.
8. A product for whitening and lightening spots, which is characterized by comprising the whitening and lightening spot composition as defined in any one of claims 1 to 6;
further, the content of the whitening and spot-lightening composition is 0.5-5%, preferably 1-3%;
the product is a skin care product or a skin external medicine.
9. The product for whitening and lightening spots according to claim 8 is characterized by comprising the following components in parts by weight: 0.5 to 5 parts of the whitening and spot-lightening composition according to any one of claims 1 to 6, and 1 to 5 parts of isononyl isononanoate, 1 to 5 parts of cyclomethicone, 1 to 5 parts of dimethicone, 01 to 3 parts of cetostearyl alcohol, 1 to 2 parts of fatty acid monoglyceride, 0.5 to 2 parts of beeswax, 0.5 to 2 parts of stearic acid, 3 to 7 parts of glycerin, 5 to 15 parts of butanediol, 101 to 3 parts of polyglycerin-101, 0.1 to 0.3 part of carrageenan, 55 to 70 parts of water, 0.2 to 0.8 part of phenoxyethanol, 0.02 to 0.08 part of chlorophenyl glycoside ether;
further comprises the following steps: 1 part of the whitening and spot-lightening polypeptide composition of any one of claims 1 to 6, 1 part of the whitening and spot-lightening herbal composition of any one of claims 3 to 6, 3 parts of isononyl isononanoate, 3 parts of cyclomethicone, 2 parts of dimethicone, 1.5 parts of cetostearyl alcohol, 1.5 parts of fatty monoglyceride, 1 part of beeswax, 1 part of stearic acid, 5 parts of glycerol, 7 parts of butanediol, 102 parts of polyglycerol-102, 0.2 part of carrageenan, 66.25 parts of water, 0.5 part of phenoxyethanol and 0.05 part of chlorophenyl glycoside ether.
10. The method for preparing a product for whitening and lightening spots according to claim 9 is characterized by comprising the following steps:
(1) preparation of aqueous phase: mixing glycerol, butanediol, polyglycerol-10, carrageenan, water and chlorphenesin, heating to 80-90 ℃, and preserving heat for 10-60 min;
(2) preparation of oil phase: mixing isononyl isononanoate, cyclomethicone, dimethicone, cetostearyl alcohol, fatty acid monoglyceride, beeswax and stearic acid, heating to 70-80 deg.C, and keeping the temperature for 5-30 min;
(3) emulsification: mixing the water phase and the oil phase, homogenizing, and cooling to below 45 deg.C to obtain semi-finished product;
(4) and adjusting the pH value of the semi-finished product to 5.5-6.5, and then mixing the whitening and spot-fading polypeptide composition and/or the whitening and spot-fading herbal composition with the semi-finished product and phenoxyethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010549169.8A CN111494224A (en) | 2020-06-16 | 2020-06-16 | Whitening and spot-fading composition, skin care product and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010549169.8A CN111494224A (en) | 2020-06-16 | 2020-06-16 | Whitening and spot-fading composition, skin care product and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111494224A true CN111494224A (en) | 2020-08-07 |
Family
ID=71865528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010549169.8A Pending CN111494224A (en) | 2020-06-16 | 2020-06-16 | Whitening and spot-fading composition, skin care product and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111494224A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113876669A (en) * | 2021-11-16 | 2022-01-04 | 北京青颜博识健康管理有限公司 | Anti-saccharification traditional Chinese medicine composition, preparation method thereof and application thereof in beauty products |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362088A (en) * | 2015-12-22 | 2016-03-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for skin whitening and spot relieving |
| CN105996641A (en) * | 2016-07-15 | 2016-10-12 | 四川吉晟生物医药有限公司 | Method for producing nerve-soothing health pillow by comprehensively utilizing rhodiola rosea |
| CN107157865A (en) * | 2017-07-25 | 2017-09-15 | 四川吉晟生物医药有限公司 | A kind of anti-wrinkle combined containing gadol extract and active peptides repairs cosmetics |
| CN107296768A (en) * | 2017-07-25 | 2017-10-27 | 四川吉晟生物医药有限公司 | A kind of whitening cosmetics combined containing gadol extract and active peptides |
| CN107375005A (en) * | 2017-08-07 | 2017-11-24 | 深圳市维琪医药研发有限公司 | A kind of antioxidation and peptide composition and its application for suppressing B16 cell |
| CN108056929A (en) * | 2016-11-07 | 2018-05-22 | 珠海联邦制药股份有限公司 | A kind of peptide composition for inhibiting melanogenesis and application |
| CN108703894A (en) * | 2018-08-21 | 2018-10-26 | 广东博然堂生物科技有限公司 | It is a kind of that there is whitening, anti-ageing complex polypeptide composition and preparation method thereof |
| CN109157429A (en) * | 2018-09-20 | 2019-01-08 | 深圳市维琪医药研发有限公司 | A kind of active peptides and tyrosinase inhibitor composition for whitening spot-removing |
| CN109432395A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | A kind of whitening spot-removing active peptides |
-
2020
- 2020-06-16 CN CN202010549169.8A patent/CN111494224A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362088A (en) * | 2015-12-22 | 2016-03-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for skin whitening and spot relieving |
| CN105996641A (en) * | 2016-07-15 | 2016-10-12 | 四川吉晟生物医药有限公司 | Method for producing nerve-soothing health pillow by comprehensively utilizing rhodiola rosea |
| CN108056929A (en) * | 2016-11-07 | 2018-05-22 | 珠海联邦制药股份有限公司 | A kind of peptide composition for inhibiting melanogenesis and application |
| CN107157865A (en) * | 2017-07-25 | 2017-09-15 | 四川吉晟生物医药有限公司 | A kind of anti-wrinkle combined containing gadol extract and active peptides repairs cosmetics |
| CN107296768A (en) * | 2017-07-25 | 2017-10-27 | 四川吉晟生物医药有限公司 | A kind of whitening cosmetics combined containing gadol extract and active peptides |
| CN107375005A (en) * | 2017-08-07 | 2017-11-24 | 深圳市维琪医药研发有限公司 | A kind of antioxidation and peptide composition and its application for suppressing B16 cell |
| CN108703894A (en) * | 2018-08-21 | 2018-10-26 | 广东博然堂生物科技有限公司 | It is a kind of that there is whitening, anti-ageing complex polypeptide composition and preparation method thereof |
| CN109157429A (en) * | 2018-09-20 | 2019-01-08 | 深圳市维琪医药研发有限公司 | A kind of active peptides and tyrosinase inhibitor composition for whitening spot-removing |
| CN109432395A (en) * | 2019-01-22 | 2019-03-08 | 宇肽生物(东莞)有限公司 | A kind of whitening spot-removing active peptides |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113876669A (en) * | 2021-11-16 | 2022-01-04 | 北京青颜博识健康管理有限公司 | Anti-saccharification traditional Chinese medicine composition, preparation method thereof and application thereof in beauty products |
| CN113876669B (en) * | 2021-11-16 | 2023-10-31 | 北京青颜博识健康管理有限公司 | Anti-saccharification traditional Chinese medicine composition, preparation method thereof and application thereof in cosmetic product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6352685B2 (en) | External preparation for skin | |
| CN105381007B (en) | External medicine composition, preparation with white-skinned face function and its preparation method and application | |
| CN105362088A (en) | Polypeptide composition for skin whitening and spot relieving | |
| KR20070087552A (en) | Skin whitening preparation for external use, whitening preparation, whitening method and method of producing skin whitening preparation for external use | |
| WO2021017835A1 (en) | Enhanced whitening cosmetic composition | |
| CN109431908B (en) | Whitening and moisturizing cream, preparation method thereof and whitening cosmetic additive | |
| US20140356468A1 (en) | Composition containing paper mulberry extracts | |
| CN109106677A (en) | A kind of composition and its application with whitening function | |
| CN112022776B (en) | Whitening essence and preparation method thereof | |
| US20060280704A1 (en) | Topical depigmenting formulations comprising an extract of bellis perennis | |
| TW577748B (en) | External preparations for skin whitening | |
| CN115887518A (en) | Anti-glycation application of sweet wormwood herb extract | |
| KR102350285B1 (en) | Skin whitening cosmetic composition comprising vitamin c derivatives and extract of mascut bailey a | |
| CN111494224A (en) | Whitening and spot-fading composition, skin care product and preparation method thereof | |
| CN1794967B (en) | Whitening and antioxidative cosmetic composition containing resveratrol and method for preparing the same | |
| CN114042001A (en) | Whitening composition with synergistic effect and application thereof | |
| CN111714390A (en) | Whitening essence milk and preparation method thereof | |
| CN113208959A (en) | Composition for inhibiting melanin generation, whitening essence, and preparation method and application thereof | |
| CN108498412B (en) | Fat-soluble glabridin compound whitening agent and application thereof | |
| JP2007063191A (en) | New bleaching agent | |
| TW202106323A (en) | Use ofrosmarinus officinaliscallus extract for manufacturing composition inhibiting skin aging and a culture medium for inducingrosmarinus officinaliscallus | |
| CN114869817B (en) | Composition with whitening effect and preparation method thereof | |
| CN111743798B (en) | Multi-effect anti-aging skin care product and preparation method thereof | |
| CN114533613A (en) | Whitening cosmetic composition and preparation method and application thereof | |
| CN115475119A (en) | Composition for whitening and brightening skin and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |
|
| RJ01 | Rejection of invention patent application after publication |